# Pharming Group N.V.: financial statements, quarterly

PHAR · Nasdaq · CIK 1828316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/phar.md) · [Financials](/companies/phar/financials.md) · [Filings](/companies/phar/filings.md) · [Insiders](/companies/phar/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/phar/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2018-12-31) | period not labelled (2019-12-31) | period not labelled (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [91.9](/filings/0001628280-22-008574.md) | [74.3](/filings/0001628280-23-010793.md) | [205](/filings/0001828316-24-000008.md) | [192](/filings/0001828316-25-000017.md) | [207](/filings/0001828316-26-000015.md) | [61.7](/filings/0001828316-26-000015.md) | [54.9](/filings/0001828316-26-000015.md) | [145](/filings/0001828316-26-000015.md) |
| Current assets | $m | not reported | [119](/filings/0001628280-22-008574.md) | [263](/filings/0001628280-22-008574.md) | [249](/filings/0001628280-23-010793.md) | [278](/filings/0001828316-24-000008.md) | [316](/filings/0001828316-25-000017.md) | [278](/filings/0001828316-26-000015.md) | [299](/filings/0001828316-26-000015.md) |
| Total assets | $m | not reported | [256](/filings/0001628280-22-008574.md) | [418](/filings/0001628280-22-008574.md) | [397](/filings/0001628280-23-010793.md) | [426](/filings/0001828316-24-000008.md) | [463](/filings/0001828316-25-000017.md) | [400](/filings/0001828316-26-000015.md) | [500](/filings/0001828316-26-000015.md) |
| Current liabilities | $m | not reported | [114](/filings/0001628280-22-008574.md) | [76.8](/filings/0001628280-22-008574.md) | [46.8](/filings/0001628280-23-010793.md) | [59.7](/filings/0001828316-24-000008.md) | [78.0](/filings/0001828316-25-000017.md) | [73.8](/filings/0001828316-26-000015.md) | [116](/filings/0001828316-26-000015.md) |
| Shareholders' equity | $m | [64.1](/filings/0001628280-22-008574.md) | [117](/filings/0001628280-23-010793.md) | [183](/filings/0001828316-24-000008.md) | [193](/filings/0001828316-25-000017.md) | [205](/filings/0001828316-26-000015.md) | [219](/filings/0001828316-26-000015.md) | [221](/filings/0001828316-26-000015.md) | [277](/filings/0001828316-26-000015.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 701,680,440 at 2025-12-31, from the cover of the [20-F/A filed 2026-04-13](/filings/0001828316-26-000019.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.